David Krupa - Concepedia

Author

David Krupa

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

D A Krupa, D Krupa, D. Krupa, DAVID KRUPA, David A. Krupa, David Krupa

Publications

2.3K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Probity Medical Research Baylor University Medical Center Icahn School of Medicine at Mount Sinai Dermatology Consulting Services

About

David Krupa is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, endocrinology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	15	1K
2	Health Sciences	3	3	379
3	Education	2	2	132
4	Engineering	1	1	57
5	Natural Sciences	1	1	55

David Krupa

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Ian Chapman, Mark A. Bach, Eve Van Cauter, The Journal of Clinical Endocrinology & Metabolism AgingGh AxisHuman GrowthMetabolic SyndromeBody Composition	1996	260
Two-Month Treatment of Obese Subjects with the Oral Growth Hormone (GH) Secretagogue MK-677 Increases GH Secretion, Fat-Free Mass, and Energy Expenditure<sup>1</sup> Johan Svensson, Lars Lönn, John‐Olov Jansson, The Journal of Clinical Endocrinology & Metabolism	1998	161
A Randomized, Placebo Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Rofecoxib in the Treatment of Chronic Nonbacterial Prostatitis J. Curtis Nickel, Michel A. Pontari, Timothy Moon, The Journal of Urology	2003	156
Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585 Gerard J. Hickey, Jennifer E. Drisko, Terry D. Faidley, Journal of Endocrinology	1996	99
Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. B. J. Gertz, Jeffrey S. Barrett, Roy Eisenhandler, The Journal of Clinical Endocrinology & Metabolism Human GrowthPeptide ScienceGastrointestinal Peptide HormoneReproductive EndocrinologyPituitary Gland	1993	98
Alendronate in Early Postmenopausal Women: Effects on Bone Mass during Long-Term Treatment and after Withdrawal<sup>1</sup> Pernille Ravn, Stuart Weiss, Jose Adolfo Rodriguez-Portales, The Journal of Clinical Endocrinology & Metabolism	2000	98
In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin Ken Bartizal, George K. Abruzzo, Charlotte Trainor, Antimicrobial Agents and Chemotherapy Vitro Antifungal ActivitiesAntifungal AgentTetrahydroechinocandin BAntifungal AgentsVivo Anti-candida Activities	1992	93
Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-1, ACTH, cortisol, prolactin, insulin, and thyroxine levels in beagles Thomas M. Jacks, Gerard J. Hickey, F.R. JUDITH, Journal of Endocrinology Animal PhysiologyVeterinary PhysiologyGrowth HormoneIntravenous AdministrationEndocrine Mechanism	1994	84
Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women<sup>1</sup> M. Gail Murphy, Michael R. McClung, Thomas J. Schnitzer, The Journal of Clinical Endocrinology & Metabolism	2001	79
Evaluation of water-soluble pneumocandin analogs L-733560, L-705589, and L-731373 with mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis George K. Abruzzo, Amy Flattery, Christopher Gill, Antimicrobial Agents and Chemotherapy	1995	79

Page 1